天津发展：力生制药前三季度归母净利润3.71亿元 同比增加119.05%

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical (002393), reported a total revenue of 1.007 billion yuan for the nine months ending September 30, 2025, representing a year-on-year decrease of 1.61% while the net profit attributable to the parent company increased by 119.05% to 371 million yuan, with basic earnings per share of 1.44 yuan [1] Financial Performance - Total revenue for Tianjin Lisheng Pharmaceutical for the nine months was 1.007 billion yuan, down 1.61% year-on-year [1] - Net profit attributable to the parent company reached 371 million yuan, marking a significant increase of 119.05% compared to the previous year [1] - Basic earnings per share stood at 1.44 yuan [1]